Day One Biopharmaceuticals, Inc. (DAWN)
| Market Cap | 1.39B |
| Revenue (ttm) | 101.95M |
| Net Income (ttm) | -84.29M |
| Shares Out | 100.85M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,514 |
| Open | 13.92 |
| Previous Close | 13.84 |
| Day's Range | 13.63 - 13.92 |
| 52-Week Range | 11.51 - 18.07 |
| Beta | -1.52 |
| Analysts | Strong Buy |
| Price Target | 36.17 (+163.15%) |
| Earnings Date | Oct 30, 2024 |
About DAWN
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmac... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for DAWN stock is "Strong Buy." The 12-month stock price forecast is $36.17, which is an increase of 163.15% from the latest price.
News
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (...
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializin...
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendin...
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDA TM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call a...
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
BRISBANE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targ...
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
Achieved $8.2 million in OJEMDA TM (tovorafenib) net product revenues in initial 2 months of launch
Day One Announces Oversubscribed $175.0 Million Private Placement
BRISBANE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing a...
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Day One Biopharmaceuticals (Nasdaq: DAWN) (Day One), announced today a new global partnership outside...
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and comm...
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Day One Biopharmaceuticals is a leader in pediatric oncology, with a focus on addressing the unmet needs of pediatric cancer patients. The company has a strong financial position, with enough cash to ...
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and comme...
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting Data subsets to be shared today in plenary oral presentations at the 2023 Society fo...
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30, 2024 BRISBANE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceu...
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
BRISBANE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and comme...
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch
Day One Biopharmaceuticals, Inc. is awaiting an FDA filing decision on its lead drug tovorafenib for the treatment of pediatric low grade glioma in mid-November of 2023. The company is also running a ...
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FD...
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
Results from FIREFLY-1 demonstrate overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated Response Assessment Neuro-Oncology High-Grade Glioma (RANO-HGG) ev...
Diving Into Day One Biopharmaceuticals
Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received first approval for pLGG. However, its lead candid...
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BRISBANE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted the...
Day One Announces Pricing of Public Offering of Common Stock
BRISBANE, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted the...
Day One Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing t...